NCT07058012: A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Sponsor: NSABP Foundation Inc. Phase: PHASE2. Conditions: Colo-rectal Cancer